<SEC-DOCUMENT>0001075880-13-000014.txt : 20130220
<SEC-HEADER>0001075880-13-000014.hdr.sgml : 20130220
<ACCEPTANCE-DATETIME>20130219175657
ACCESSION NUMBER:		0001075880-13-000014
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130218
FILED AS OF DATE:		20130220
DATE AS OF CHANGE:		20130219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		13624600

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cs6.htm
<DESCRIPTION>CONVERTED BY EDGARWIZ
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Converted by EDGARwiz</TITLE>
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:553.333px"><P style="margin:0px"><BR></P>
<P style="margin-top:0px; margin-bottom:16px; padding-left:-30.4px" align=justify><img src="cs6001.jpg" alt="[cs6001.jpg]" align=middle></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify><B>18</B><B> February 2013</B></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify><B>ASX RELEASE</B><FONT style="font-size:16pt"><B> </B></FONT></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt" align=justify><B>CS-6 Highly Active Against Ovarian Cancer Stem Cells</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">Novogen announces today the results of an important study concerning its lead experimental drug, CS-6.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">The study was conducted by, Mazor Oncology, a spin-off company of Yale University with particular expertise in cancer stem cells and in assessing the likely clinical potential of new anti-cancer drugs.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">The study was designed to test the ability of the experimental anti-cancer drug, CS-6, to kill ovarian cancer stem cells.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">Cancer stem cells have been identified in a range of cancers including gut, skin, ovarian and brain cancers and leukaemia. Cancer stem cells are almost completely resistant to radiotherapy and standard anti-cancer drugs.</P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">Although representing less than about 1% of all cells present in these cancers, they are thought to be the cause of cancer relapse following radiotherapy and chemotherapy where the bulk of the tumour is replaced with new highly-resistant cells derived from the cancer stem cells. </P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">In laboratory studies, CS-6 has shown potent anti-cancer activity against cancer cells representative of a broad range of malignancies including ovarian cancer and glioma (brain) cancer, but it was important to extend this to see whether the drug also would be effective against cancer stem cells. Such dual activity, unknown in all currently approved drugs and very rare among experimental drugs, would mark CS-6 as having significant potential as a comprehensive chemotherapy, targeting both the minority cancer stem cell as well as the majority non-stem cells.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">Studies performed in the laboratory of Dr. Gil Mor at Yale University have identified and characterized ovarian cancer stem cells as the source of ovarian cancer recurrence. &nbsp;Targeting these cells, therefore, represent a critical approach to prevent recurrence, the main cause of mortality in patients with ovarian cancer. In laboratory tests conducted since Novogen acquired its new Triaxial drug technology, CS-6 has proved highly effective at stopping the growth of these cancer stem cells, eventually causing them to die.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">Dr Mor said today, &quot;ovarian cancer stem cells are among the toughest cancer cells to kill. Standard chemotherapies have no effect on them, so finding a compound such as CS-6 with the capacity to target these highly chemo-resistant cells is very exiting. &quot;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">The initial studies performed by Mazor Oncology show a highly effective </P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; page-break-before:always"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">cytotoxic effect on ovarian cancer stem cells, at low concentrations and within a short period of time.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">Dr Andrew Heaton, Novogen Chief Scientific Officer said, &quot;when we designed CS-6, we built into it years of experience in benzopyran anti-cancer drug design. We expected it to be a highly potent drug across almost all forms of cancer, but seeing its anti-cancer activity extended beyond the regular cancer cell to the originating cancer stem cells has exceeded my expectations as a drug designer.&quot;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">Professor Graham Kelly, Novogen CEO, said, &quot;our primary goal remains to develop CS-6 as a treatment for glioblastoma multiforme, the main form of brain cancer. Today<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s news raises two important matters. The first is that it shows that we have the opportunity to develop CS-6 against ovarian cancer, which like GBM, is another deadly disease for which an effective long-term therapy is yet to be found. The second matter is the hope that CS-6 might also be effective against the cancer stem cells that we know exist in brain cancer.<font style='font-family:Arial Unicode MS,Times New Roman'>&#8221;</font> </P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt">Professor Kelly added, <font style='font-family:Arial Unicode MS,Times New Roman'>&#8220;</font>it is important to point out that this is early days and we have some way to go before we will have clinical evidence, but there is no doubt that this news elevates CS-6 and the super-benzopyran family of drugs to which it belongs into an entirely new clinical dimension where we hope it will be possible to provide a comprehensive cancer treatment.<font style='font-family:Arial Unicode MS,Times New Roman'>&#8221;</font></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt" align=justify><B>About Novogen</B></P>
<P style="line-height:15.75pt; margin-top:0px; margin-bottom:30px; font-family:Cambria,Times New Roman; font-size:12pt" align=justify><FONT style="background-color:#FFFFFF">Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol <font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>NRT<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>) and NASDAQ (symbol <font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>NVGN<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>). &nbsp;The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on super-benzopyr</FONT><FONT style="background-color:#FFFFFF">an and <font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>stealth<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font> drug technologies</FONT><FONT style="background-color:#FFFFFF">. The Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s inaugural drug candidate is CS-6.</FONT></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt" align=justify><B>About CS-6</B></P>
<P style="line-height:15.75pt; margin-top:0px; margin-bottom:30px; font-family:Cambria,Times New Roman; font-size:12pt" align=justify><FONT style="background-color:#FFFFFF">CS-6 belongs to a new class of drug candidates known (structurally) as super-benzopyrans </FONT><FONT style="background-color:#FFFFFF">displaying potent anti-cancer activity </FONT><FONT style="background-color:#FFFFFF">and demonstrating increased bio-availability to cancer cells (<font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>stealth<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font> technology). CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells, with particular activity against human glioblastoma cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer.</FONT></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt" align=justify><B>Further information</B></P>
<P style="line-height:15.75pt; margin-top:0px; margin-bottom:30px; font-family:Cambria,Times New Roman; font-size:12pt" align=justify><FONT style="background-color:#FFFFFF">Contact Dr Graham Kelly, Chief Executive Officer.</FONT></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt" align=justify>T: &nbsp;(61 2) 9878 0088</P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt" align=justify>M: (61) 0459 200 095</P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:12pt" align=justify>E: <U>Graham.Kelly@novogen.com</U></P>
<P style="line-height:15.75pt; margin-top:0px; margin-bottom:30px; font-family:Cambria,Times New Roman; font-size:12pt" align=justify><FONT style="background-color:#FFFFFF">Further information is available on the Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s web site, </FONT><FONT style="background-color:#FFFFFF"><U>www.novogen.com</U></FONT></P>
<P style="line-height:15.75pt; margin-top:0px; margin-bottom:25px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px"><BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: C3B69205 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cs6001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cs6001.jpg
M_]C_X``02D9)1@`!`0```0`!``#__@`[0U)%051/4CH@9V0M:G!E9R!V,2XP
M("AU<VEN9R!)2D<@2E!%1R!V-C(I+"!Q=6%L:71Y(#T@.3`*_]L`0P`#`@(#
M`@(#`P,#!`,#!`4(!04$!`4*!P<&"`P*#`P+"@L+#0X2$`T.$0X+"Q`6$!$3
M%!45%0P/%Q@6%!@2%!44_]L`0P$#!`0%!`4)!04)%`T+#104%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\``$0@`
M@`/H`P$B``(1`0,1`?_$`!\```$%`0$!`0$!```````````!`@,$!08'"`D*
M"__$`+40``(!`P,"!`,%!00$```!?0$"`P`$$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D*"__$`+41``(!
M`@0$`P0'!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:``P#
M`0`"$0,1`#\`_5.BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**C
M9]HS@GZ=:CBE\V-&92I8=#U''-'F!8HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*0]*6
MD)XH`BDPJD]J\]^!WCQ?B'\,-"U9GWWGEM:7@`P5N(7:*4'_`('&Y]P1ZC/H
M$J[D8#@D5^<G[+G[0:?!/X]>./A_XCN5M_#FJZ_="":8[5L[WSF3#$_=5U51
M@\+L')Y)UIPYU9;GF8G%K#5H*7PRT/TAW>U.J!9=P''7KR.*FR*R\CTM]1:*
M**!A1110`444F:`%HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`&\
M$4&D)P*S-7UVRT*Q>[U"Z@LK=&"M+<2A$&3@98]*72X)-M16[-2EZBL'0_&6
MC>)7D72M3L]2,0#2"TN%DV`],[2?>MLO@'`_"E=6N5*$H.TE9CLD4O6HB^!D
MXSCN>E8VD>,]$\17$D&E:M8ZC-$NYX[:X21D7ID@'(YXIW5["2<E=(WZ*A,I
M&?EX`I'F`Y/W?7-,2U)6_*D/*&N,\3?%WP=X/G:#6?$NE:;<JNXPW-XB.!Z[
M2<@>^*H:+\?/A]XBF$&F^+](NIFX5$O$W$^@!(K-U()ZLZHX3$2CSQIRMWL[
M'>M\ZLN`<\<]*_&+]K#PT?#G[1OQ"LI-SK-JCWH,@(!$X$V/I\Y'TK]EEN/,
M4%.=V,$$'_/^>E?F%_P4D\(OH7QXL-<",L&NZ5&X8GY3-"QC<>Y"^5S_`+7M
MSZ&$:YSXSB"C)X536\6>C?L3_MDLCZ;\//'E\2PQ;Z/K-RV=^!@6\K'^(9`5
MSU'!]:^_HY@Z@@'D9QW%?@49,Y8]>[$\G!]>WU'-?IW^PI^T_)\4]$;P7XFN
M@_BW1X08;B0_-J%LN%WM_P!-5RH<#.<JWJ!KBJ'VHG%DN:.=L/5>O0^PJ0U'
MOQC(P3ZGFG;CZ5YQ]L+CC)ZT8KGV\:Z(FL+I+:K9+J;':+,W*B8L1N`V9SG'
M.*V1.<G*@`#D@Y`/I0M=ARA*/Q*W4G^M(1@]JP/$?CK0_"-OYVMZK9Z7%_ST
MNIUC4GTYKD8?VD_AE<SF"/QMHS2`XP;M0/SZ5#G&+LV=$,+B*L>:%.37DF>G
M#Z4N/6LS3-:L]:M4N;&YAN[>0966&0.K#M@C(-75EW`<`'H1W%6<[BXNTE8G
MHIA?"YQFHI+E8U))7CJ,T"W)CQ0.:\_USXZ^`?#5PUOJ7BW1[2X0D-"]XF]?
MJN:32OCW\/M;F6&R\8Z-<2,,JJWB9/ZUG[6'<Z_J>)Y>?V<K=[,]#HJG;WD=
MW&KPNLB,,JZG((^O^%233K#$TDA$:*,LS-@`>N:JZ:N<C33L3X-&#7'#XL^#
M^<^*-&49P"=0B`/YMU]J>/BOX-8<>*=&SZ&_B_\`BJ7/'N;>PJ_R/[CK?PH.
M,5SVB^.-!\1SR0:5K%AJ4T:AW2TNDE95)QDA2<"M/4=5M=*LI;R]N(;.UB&Z
M2:=PB(/4L>`/>JOU,W"47RM69>HZ5@:+XWT/Q#.T&EZK8ZC,@W/':W*2,J^I
M`-;@E!R`,TDU)702A*#M)68^EZBHRWRY/&*P=+\;:%K6I2Z?8:O87EY%G?;P
M72/(N#@Y4'/!XHNE9=Q*,I7:6B.CHI`<TM4(****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"D/W:6D/2@",\Y]\U\\?MUH#^SKKF0&S+;<
M$9S^]7_'O7T0>#BOGK]NL8_9VUWG'[ZW_P#1R5SUOX4CU\HL\PHI_P`R/AOX
M)^/=7^`'BSP]XT6$_P#"/:JTUO<QQ#(N(4?;,`!_RT0J&QZ=^>/U4T+7+3Q%
MI%GJ>GRI<6EW$LT4T;`JR,H*D'T/%?%7P7^"]M\:_P!CV;2PL<6KVNH7MSIM
MR1@QW`E<CGL&'R'M@]#C!L?L+?&6ZT?4[SX6>),VEU;R2G38KCAD96/G6W/]
MTY91Z;NV*\["SE2Y8R>C/L<^I0S/VM:FOWE)VE;K'H_D?;-Z2+>1>VSJ:^!?
M^"=\:)\4_&TB@!FL06.U1G-PWMG]37WO<L9(G'`&WD@]:^"_^"=Y(^*/C4CM
M8J?_`"8:NVMK4@K[GSV6QME^+;5](OTU/OUR`.<8SZU\*_M0?M5Z_KOBN3X>
M_#N2:.0S_8I[ZQ!:>YN"<&"#T'4%O4$<8S7U)^T#XXG^'OP<\6:];-LO+2Q?
MR&_Z:D;4/X,0:^4/^">GPPM]6UK7/&U\@GDL";"S=QG]ZX#RRY/\1RH_[Z.>
M<#/$3<I*BNITY-AZ-'#5<RQ,>90LHK^\]C6^&/\`P3ZAU&V34_B#K5W)>S?O
M6L;!Q\C'G]Y,X,COSVV@'UKH/'/_``3N\+7]@\OA/6;_`$?447,4=XPN868>
MI/SJ2>ZMQUP:^OPAQC/7VXI=FU2<CIZ5HL)170X)\09A*IS\[7DK6^X_.+X5
M?'CQK^R]X^/@OQY]HO-!A=8YK>1S*ULC=)[=VP7BXZ<<9X!X/K7_``40\!Q_
M$#X%Z9XQTSR[Q]`G2\%Q&05>SG`21E/<9,3Y]%-;?[>_PTM/$/PN3Q7'"#J?
MA^8-YJ_>>WD8)(A]@6##T*@T_P#8NU:#XI?LX7OA77=M];63SZ-/%(<[[9T!
M5?8!7*@<X"BIPU2>'Q'LWMT.G/\`"4<YRI9A2CRR;Y9);-VT?S/RM*')SP1U
M'I[?UKH/`?C;5?AQXPTGQ/HDIAU/2YUGAR?E<`\HWJ&4LI]0S>Q&U\9?A=J'
MP7^).M>$M2!,EE+OM[@J0MS;N#Y4@^HRN.<%&&3@$\)GL1FOLKJK`_FJ4:F%
MJM;.)^Z'PU\<:=\1_`^A^)M*;?9:K:I=1C()3<,LI]"K94CL01VK8U[6(-"T
M>]O[J01P6L#S2.W1549)_2OC+_@F3\1VU?P+XC\%W,FZ31KI;VT!8EOL\XRR
MX[`2I(V?63MCGTS]NSXBCP7\%KK3(IS#>Z_(+!"APRQ8WS-_W[5Q]2*^:Q+5
M'F;V1^U9&GFDJ,([RM?]3Q']CK1)/C%^T)XJ^)VHVRM':2//"[+G$LV5B`SW
M6$=N[#I7NO[5_P"TPOP4TF#2='\FX\6ZC&3`)>4M8QD-.X[X[`XS@\\8.C^Q
MW\/?^%>_!#2'NH?)U+5B^IW:D=&D^XI_W8U1>W0\#.*^1-%L1^TS^V)=#46:
MZT:749973JIL;8E43V#;%!]3(WK7DMSA2C%/WI'Z)3IX?'YE6KUHWHT%MWMH
ME\V;_P`)?V5_%O[1VWQGX^\07UK87G[V!YU$EY.A)Y56RD4?]WY22.<"O;=2
M_P"">GP[GTOR+6^UFSNU`Q<?:Q*,^\;J4`]E45]006<=K'&D*)%$G`1%PHXP
M,#MZ59$>"2#75#"PBO?U9X6(X@QM2IS49<D5M%=%V/S0\1^%?B7^Q+XJL[S3
M-3>]\,W,I6-XU;[)<G.3%-$2?+D*@@%3@GT-?=?P3^+>E?&;P'9>(]-_<L_R
M75J6RUM.!\\9X&0.H.!D$'`S6E\4/A]IWQ*\#:SX=U-1+:WT#("P&8WQ\C+[
MJV&!ZY'6OB7]@GQ)J/A#XQ:]X,O9"/MD$IFB)R!<6S;"P]"5)!'^RM8I.A54
M6_=EL>I4<,\RZ=>44JU*S;6TEY^9][ZYKUEX<TB]U/4[A+/3[*)Y[FXF.$BC
M499C[8K\_P#QC\8_B-^UUX\F\*>!&GT;PTI)\L,828<X\ZYD'S*"#D(OL.>2
M/7?^"A?CR;0/A[H_ARUE,3:S=E[@@X)AA`8K]"Q4D^BXP<\=M^QE\*[3X?\`
MP9T6_6)!JNN1)J-U,1EG5U)B7/4!48''JS>M.JY5JWLEHEJS'`PHY9E[S*K'
MFJ3?+!/96W9YWX4_X)S>&K6VB?Q)XDU/4+P_,Z6(C@AW>JY#/GWW9/M4GBC_
M`()Q>#[R*1M&\0:MILF#L2<0W,0/KADW9]PP-?8!A&!@XQW[_2G%<CMGU(K?
MZK2_E/+_`-8,RYN;VK]-+?<>&?LN_!37O@KX7U/3=?UHZQ+/>%[=(II&@@A"
MX7RT?)0L2Q(!(`V@'CGU;QL%;P=K*]OL<O7_`'#6X%&0=V2.*Q?'&$\(:T><
M?8YNG^X:U<5"#2/,]M+$XI59[MK\S\UOV3OV;-!^/[^)1JVHWNE-I?D&+^SA
M"-_F&7=NWHV?N?K7T+_P[;\$8)/B?7_RM,?^B*Y/_@FW/':3>//,=8]WV(+O
M(7)!GR/?J*^X9+^V5?\`71$=_G'%<-"E1E33:_$^QSK-,PP^-G3HS:6EM%V7
MD>(_`?\`9/\`#_P&\0ZAK.DZOJ6HSWUJMI(MZ(=H56W`C9&ISGUS6O\`M8)_
MQCOX['WP--<X*YSR/SZ]*];BE66,/&0Z$<%3D&O*?VL2!^SMX\.<$Z:_3KU%
M=DHQITVH*VA\OAZ]7$8ZE5K.\N9?FNA^<7PI\3:Y\%M?\/\`Q#TNV+Z9)>S6
M$BQ\"Z5`IFB;`X8JP9#SGTXK]6/!?BK3?'/AO3M=TBX6[L+^!)H94/WE/?Z]
M>.Q!KXY_9<^%-A\8_P!E?Q/X=O!Y<DVL3R6MRJY:VN%2)DD7T^;MZ'&>]4_V
M,OBOJ'PQ\>:C\)?%1-KOO)%LUD;Y8+L9WQ+Z)(H#H/7=C.:\[#3E0Y8O:7YG
MVV>THYI[:<$O:T79VZQ[_(^\)EW1L!P<9YK\Z_V.;=/^&KO$A5%!7^TF!"@'
M'VIN,XYZ]Z_1%IE:)F/`VYYK\\_V-SC]J[Q-CTU0?^39KHQ',ZE-)]3Q,CBG
M@L:WTBK?>?HJHP*=31]RG5Z)\<%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!112'@$T`,?K7SU^W5_R;MKG_`%UM_P#T:M?0IZC/>OGG
M]NEL_L[ZX/\`IM;_`/HY:YZ_\*1[&3?\C"BO[R*7[`RY^`<7&0=2O!]?WIKR
M?]MWX0WGA#Q+8_%3PONL[A)XS?RP`DPSJ0(I\>APJOZ@#WSZS^P)S\`H1G!_
MM.\_]&M7O/B/PW8^*M"O])U*W2ZLKR![>:)QD,C#!!_,UA"FJE"*/7K8^6`S
MFK5WCS--=TSS_P"`GQAM?C/\,K77(!Y%]&IM[^U;[UO<*,.GN.0P/&0P]\?+
M/_!.W_DJ/C8#K]A7_P!'M7.^"=4U3]CC]H:Z\/:I)(WA?4V2)YY"=LEJS8AN
M/]]&;:Y]"3Z`;_\`P3N93\3_`!J4=7C:Q!5UZ$?:'P?RP:XU4<ZE.$OB3=SW
M*F`^JX/%U:6M.:C*+\K[?(^BOVU[*2[_`&<_%1B)`B2&9PO=5F5F!]L`UPO_
M``3LO()/A3K5KN5KFWU>0OMZX>-&4D=N#C\*^DO'?A:U\;>#]9T&\7-IJ%K)
M;N/9E(R/SK\Z_@#\0[[]E?XTZEX=\6!X-/G866HN<GRV5OW-V!CF,J6!/;=U
M..=ZS]G7A4>VQY>6_P"W916P5/XTU)+NEN?IKBD9MJ$GI6;8:Y9ZI9QW=I<1
M3V\J"1)4;*.I&00W0C%799PL1)8+]37I]+GQ+C*+Y6M>W4\A_:MU*TTG]G_Q
MM/=+OC:Q:!5`R=SL$'_CQ!S_`(5XQ_P3>T^XA\&>,+EU/D3:A'&C9ZLL0W<=
MN&4_C7"_MN?'JW\>:A:>`?#3G4;6VN%:^EM_G\^Y!VQV\>/O%6)SV)*CL:^J
M?V9?A9+\)OA!HVBW2*FJR@W>H%3D">3EESWV@*F>,[<X&<5YB:JXE271'W%6
M#R_(O8UM)5I)I=4EU\CCOVP_V9H?C[X)BN=+2*+QCI2/)I\S_*)U/WX7/HV!
M@G[IYYY!_)S5].N]%U"YT_4+2>QU"TE:">UN$V2QNIPR%>S#N.PP>003^]IC
M)'WB.,?2OE3]L+]C^T^-6FMXI\-0I8>.;2')XV)J:`?ZJ3TD`R%<\\[22`-O
MT6&K^S=I'XUF^5+$KVU)>\NG<^2/^">WBE_#G[2.G67FA8=9L[FQDST)"^:/
MQW1C\S7M/[04Q^/W[6?AWP)`YFTO2W6"Y4<J,8FNC_W[$:?5B/:OC?X5^))_
MA3\6_#>NZC;3VL^@:I')>6C#9*"C%98V'8XW*??/H<?<W[!'A&Y\4>)?&/Q)
MUA3)>W-R]M$[C)\QV$LY'T+*N?08[5QYI'GJ0BNNI]5P//ZK@L1BY[P]U>K7
MZ'V<+5+335AB4*L:;%`&,`=J_.O]B&\3PW^TIJ>GWJ&&\N+2[LUC89(E242,
MN?95/XU^D3`%2,9'I7YL?M(>%M8_9Y_:,@\=Z-$QT_4+PZO:MNVHTK'_`$B!
MB>`S$NV#_"_LV/+Q2Y)0J+H?9Y!-5HXC"-^]4CIYM:V/TF#CCGCCGL:>>E<%
M\+OBOH7Q<\+VFMZ)<[XI.)K9LB6WDQ\T<BXRK#KSCL>]=WY@&<]J]",E+5'R
M52E4HS=.<6I+=,AN740L21C;GGBOSC_9G`UG]LV^N[63?!]KU>XWH."A<C/T
M)8'/X>]?3O[6/[1%C\)_!5SIFGW"2^+M2@:.TMXV&ZW1LKY[_P!U0?NYQN8`
M#GIY;_P3W^%5QI]OK'CN_CDC2_`L=->48:6%26>5?57;D'N%KSJS56M",?LO
M4^URN,L#E6*Q%9651*,;]7?H8W_!2/3IAJ7@J[`W1&&[@7'(#DQL1^7Z9]*^
MM/@CJT&O?"+P;?6Q7R9M*M2`A&%(B7<OX$%2.Q!KBOVLOA)-\7OA+>6=C%OU
MK3W%_8H/O22*I#1CIRREE],D>E?/?[%'[2%IX1C7X=^*95TZ'[0XTNXF)54<
MO\]N^?NG?G!;&3N7`.,E_98B4GLTA.#S+)(*CK.DW==;/J??-9'B/5UT#0-1
MU)XVE6S@DN#&F-SA5+8&>_%7H[N.4`JP8$9!4YKGOB6V[X?>)%QG.G7`XZ_Z
MMJ]%M\K9\;2A>K&$ENU^9YS^SS^TI9?M!1:R]GHEWI']F-"K_:W#;S(&Z;?3
M;^.>U>G^.<#P;K9YXLY>G7[C5\;_`/!--D$/CDX`)DLB`!@X*2]1]>*^Q_'0
M(\':S@X_T.7MG^`USPDYT>9]4>QCL-#"9C[&DK)-?H?F;^S/^SY=?':7Q"EM
MXFG\.?V;Y))@5F\X2&7`;#KTVGKG.>U>ZG_@GGJL1!/Q,OSSP!`^3_Y$XJC_
M`,$VLI<>/-P*\6).1@<F<CZ]#7W,</UX&.N<URX:A"=--IH^DSO.\;A\;*E"
M?NJW1/HNMCBO@]X"D^%WP\T?PU/J,FK2Z?#Y37LBE6E)).2"3_,US/[6"?\`
M&.OCH@Y`T]_Z5ZRK`@AADCK@\UY1^UB^/V=_'2C_`*!S_P`Q794A:E)+LSY#
M!U)5,=2G+63DG^)YG_P3N/\`Q9;5#ZZW<#_R'%7+_MU?!&:2&W^)OAU'M]3T
M_:NHFV^5]BG*7`]&C/?LN:ZC_@GA%N^"NJ#)_P"0U/R.#_JXJ^FM1TRWU2RG
MM;R&.YMIT,<L4B[E=6&&!!['TK&G353#QB^Q[>,Q\LOSNI76J4G==UU1Y!^S
M+\:X?CC\,[>[G=5UZQ'V74X0-I#@9$@'97&T^QW#J#CY9_8Y./VK?$I'IJ7_
M`*5M5&ZM]2_8K_:17R=[^#]4'RY)VR63-SZ_/"3]2,=-^3=_8OE2Y_:H\12P
MNLL,D>HR(XZ/&UR65AZ\,O';-<+J-U*=.>Z>I])'`PP^%QF)H.]*I"\?*[V^
M1^BX^Y3J:/N4ZO</RT****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"D/2EIK#(H`C/)(]\UXY^U7\/]:^)WP;U30O#UO%<:G</"\<<\HB4
MA9%8_,>G`KV3R\Y&>V*#&&&#R#V-3.*G'E9OAJ\L-5C5AO%W1XC^R1\.M<^%
MOPCCT/Q';PVNI+?7,QCAF$B[&<D<CV/2O;CT],4@C)49;D=QQ3RHP<TH14(J
M*Z!B*TL35E6GO)W9\_?M9_`,_&;P.9M+A#^)](S-8GA?.!XDB)/9AS]0M>7?
ML/\`P7\:_#/QKXCO/%.BR:7;W-A%'$SRHX9Q*6(&WIU[U]G"//).3ZX]J/)"
MGJ.GI7/+#1E557JCUJ6=8JE@)Y>W>$OP6^@':2`03Q7B?[07[,FA?'6Q6>1A
MI/B&U7%KJL*9(_V)!D;TXZ$\=O?V_'/6D`R#DYKHE",URR1Y.&Q-;"5%5HRM
M);'Y]:5\+/VD/V?F:U\*7!U?2`^8X+5TG@(SWADP4)]$(^M3ZWIG[4_QDBFT
MN_MYO#NFR@)*L31V,3`\'+*7D(P>0#CVK[\$0Z]#CKCD4OE\Y.,^N.:XOJBV
MYY6]3Z9<0ROSRH0<_P"9QU_,^8?V>?V,-)^%6I0>(_$,\>M^)DRT/EQE;:T8
MCJBDG+#U.!WQGFOIM1M/;&>P]_\`]=/"$'KQZ4H!'4YKKA2C37+#0^=Q>,K8
MZJZU>5V_N0\@$$'D&HWC^5L8R>Y'7ZU-36&00#@^M:G(?`?[>?[+6I:YXATS
MQUX%\/W6K:A>2?9M4T_3D#,[A2T=QC/!(4HYYSA#P2=WUA^S_P##I/A9\*_#
M_A\QE+J"V$ET6'S&:0EW)]3N8CVQ7HHAPP.[CT%.6(+],YQ3DW*S>Z,J,/81
ME"GI&3NUYV'%<GU&*XSXG_"_0_BOX6N="\06WVBSF^96&!)`X!"R1M_"XSUY
MXR,')SVFW..:&7.1G@]JEI27+(WIU)TYJ<'9K9GY^ZG^R3\7?@CXBGUCX::\
MVH0#HL$@@G:,9*I)&V4E"]L]^@%7+CQE^UAK-NNF?V1+9.?W;7<=G!$[9XY=
MF([]0!ZU]Y>5D8!P/U_6D:W]\'Z9KB^JVTA*R/I_]8*E2TJ]&$Y+JXZOU/A[
MX7_L*:[XC\1#Q#\5]8-ZTLGG3Z=%<--)</QQ+,W5<<;1GCHPK[2TW3+72-/@
ML[6"*UM8$6*.&%`J*B\!0!T`Z`=JT515QV]AP*7;D<$`9[UT4J,::MU/(Q^9
M8G,9)U9:+1);+Y#"NX<Y.1TZ9_PKYA_:&_8LT3XIWEWK>@3PZ!XAN&WW0:/=
M:WS;<9E3LV.-_/!8E2<$?49!QU`_"F&+Y2/YCI5SA&HK,QPF,KX&I[2A*S_!
M^I^>FG>#?VH?@POV#1GO=2L%XC$,\5[!@=`JRG<@]AC\*TKV?]K#XAV\VGSV
M,EA:3Q&*57CMH%=6&""?F('7D8/I7WSY*X.0"3[4HA7;C:OMQTKB^J=.>7WG
MT'^L,F_:2P\.?ORGS;^Q_P#L]:_\#M-UV3Q!=64]SJ;PE(;)F<1!`1AG(&3E
ML\#\Z]Z\564VH^&]3M;=1)--;R1HI(`9BI`&3T^M;.SW.13B,GK77"FH0Y%L
M>!B,95Q6(^LU-97N?G7\/?V=_P!HOX4?;3X5CL-(-]M-P4NK:0OL+;!\R'HK
M-^==H?#_`.UZ%/\`Q-[;I_?LO_C7\J^WA&!V!.<\BG%01C`P:Y5A(I<JG+[S
MVYY_5JOFJ48-_P"'_@GS-\!],^/UGX]9OB/J$%YX:^RR*J*UL2)MR;#^[13T
MW=<UZC^T!X3U/QU\'/%6A:1`DVIWUBT,"22!%+DC@D]/K7H80[NHQ]/\^M*R
M9SC`[CCH:ZHT^6'+>YX];'2GB(XB,(Q:L[)66FIX+^QM\,/$'PF^&=_I'B:V
M@M-0EU*2Z6.&<2@HR(!R.^58?A7O?4D'IBF"%1T)SW[9[U-L&:<(*$5&/0PQ
M6(EBZTJ\_BD[L\8_:9^!L7QM^'5S8Q!$UZR+76FW!&-LH!_=D_W7'RGMG:V#
MM`KYU_8V^!/CSX>_&`ZOXB\/MINGG3I83,9E8"0LO``YP<?I7W<RAO3.,8/2
MHUM]DFX`>O3D]>/UK&>&A.HJG5'I8;.,1AL)4P2UC/3T+(Z4M)T%+74>(%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
F4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
